Real-Life Effectiveness of MP-AzeFlu (Dymista^®) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale

Figures & data

Table 1 Baseline Characteristics of per Patients in Sweden (Safety Population)

Characteristic	Patients (N = 161)
Sex, n (%)
Male	77 (47.8)
Female	84 (52.2)
Age, y, n (%)
12–17	6 (3.7)
18–65	144 (89.4)
>65	11 (6.8)
AR history, y, mean (SD)	16.0 (12.5)^a
Phenotype, n (%)
PAR only	49 (30.4)
SAR and PAR	112 (69.6)
Number of ARIA criteria fulfilled, n (%)^b
1	66 (41.0)
2	53 (32.9)
3	32 (19.9)
4	10 (6.2)
Severity of AR VAS score, mm, mean (SD)^c	61.4 (22.4)
Patients using ≥2 therapies for AR since preceding year, n (%)	119 (73.9)
Patients using immunotherapy currently or in the past, n (%)	16 (9.9)

Notes:^an = 133. ^bAccording to the ARIA classification,³ AR severity is determined by the number of ARIA criteria fulfilled. If no (zero) criteria are met, the patient is considered to have mild severity. If one or more criteria are met, the patient is classified as having moderate/severe AR. ^cOn a scale of 0 = “not troublesome at all” to 100 = “intolerable”; score >50 mm indicates symptoms of moderate/severe PER.²

Abbreviations: AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; PAR, perennial AR (allergy to ≥1 nonpollen allergen [dust mites, animal dander, and/or mould] but no pollen allergens); SAR, seasonal AR (allergy to ≥1 pollen allergen); SAR and PAR, allergy to ≥1 pollen allergen and ≥1 nonpollen allergen; SD, standard deviation; VAS, visual analogue scale; y, years.

Figure 1 Mean VAS score reduction following MP-AzeFlu use by PER patients in Sweden (N = 161). ^†p = 0.001 vs Day 0; ^‡p < 0.0001 vs Day 0.

Abbreviations: ARIA, Allergic Rhinitis and its Impact on Asthma; MP-AzeFlu, Meda Pharma’s AzeFlu; PER, persistent allergic rhinitis; SEM, standard error of the mean; VAS, visual analogue scale.

Figure 2 Mean VAS score reduction following MP-AzeFlu use by PER patients in Sweden according to (A) age, (B) sex, (C) baseline disease severity, and (D) AR phenotype.

Abbreviations: AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; MP-AzeFlu, Meda Pharma’s AzeFlu; PAR, perennial AR (allergy to ≥1 nonpollen allergen [dust mites, animal dander, and/or mold] but no pollen allergens); PER, persistent AR; SAR, seasonal AR (allergy to ≥1 pollen allergen); SAR and PAR, allergy to ≥1 pollen allergen and ≥1 nonpollen allergen; SEM, standard error of the mean; VAS, visual analogue scale; y, years.

Figure 3 Quality of sleep over time for (A) safety population and (B) AR phenotype subpopulations. ^†p < 0.001 vs Day 0 (Wilcoxon signed-rank test). Values within each bar may not add up exactly to 100% because of rounding. Missing values are not considered in this figure.

Abbreviations: AR, allergic rhinitis; SAR + PAR, seasonal AR (allergy to ≥1 pollen allergen) and perennial AR (allergy to ≥1 nonpollen allergen).

Bousquet J, Schünemann HJ, Hellings PW, et al. Macvia clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367–74. e2. doi:10.1016/j.jaci.2016.03.025

 PubMed Web of Science ®Google Scholar

Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and allergen). Allergy. 2008;63(Suppl 86):8–160. doi:10.1111/j.1398-9995.2007.01620.x

 PubMed Web of Science ®Google Scholar